Eculizumab (Alexion Pharmaceuticals, Inc, Boston, MA) is a humanized monoclonal antibody C5 inhibitor and the first complement inhibitor approved for the treatment of PNH [22]. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.